Man & Science Closes €7.4 Million in Capital Increase

Under the lead of Mr. Robert Taub, Man & Science chairman, Noshaq Spin-Offs S.A. and other existing shareholders have subscribed 70% of the financing round. The Société Régionale d'Investissement de Wallonie (SRIW) and other private investors took the ...

‍

Discover more news

January 26, 2023

Man & Science Expands its Headache Disorder Treatment Portfolio with Acquisition of Palion Medical

September 5, 2022

Man & Science announces U.S. FDA Breakthrough Device Designation Granted for the treatment of Chronic Cluster Headache

Man & Science announced today that it has been granted a Breakthrough Device Designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its minimally invasive innovative neuromodulation therapy for the treatment of Chronic Cluster Headache (CCH).

Man & Science Closes €7.4 Million in Capital Increase

Discover more news

Man & Science Expands its Headache Disorder Treatment Portfolio with Acquisition of Palion Medical

Man & Science announces U.S. FDA Breakthrough Device Designation Granted for the treatment of Chronic Cluster Headache

Contact